La AEMPS informa sobre datos clínicos observados con el uso de rucaparib (▽ Rubraca®) como tratamiento oncológico en tercera línea o posterior | Agencia Española de Medicamentos y Productos Sanitarios
Clovis Oncology, Inc. - Clovis Oncology Announces Availability of Rubraca®▽ (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Germany
Clovis continues fight for share of PARP blocker market
European Commission Approval of Rubraca_DRAFT_9May2018_v1 tl and bb comments CLEAN
Rubraca, INN-rucaparib camsylate
Rubraca, INN-rucaparib camsylate
Clovis reveals even more regulatory troubles for Rubraca
Cancers | Free Full-Text | The Development of Rucaparib/Rubraca®: A Story of the Synergy Between Science and Serendipity
Clovis Oncology Receives EMA Validation for its Application for a New Indication for Rubraca®▽ (rucaparib) as Maintenance Tre
Rubraca (rucaparib) for the Treatment of Advanced Ovarian Cancer - Clinical Trials Arena
Rucaparib (Rubraca®): interim data from Study CO-338-043 (ARIEL4) show a decrease in overall survival compared to standard of c
Rubraca (rucaparib) for the Treatment of Advanced Ovarian Cancer - Clinical Trials Arena
Applications Submitted to FDA and EMA for Maintenance Rucaparib in Advanced Ovarian Cancer
EMA's human medicines committee (CHMP) April 2022 meeting highlights
Public Summary SwissPAR - Rubraca® (active substance: rucaparib camsylate)
CHMP recommends four new medicines, including first-in-class treatment for follicular lymphoma | RAPS
EMA recommends restricting use of cancer medicine Rubraca
Rubraca receives CHMP positive opinion for ovarian cancer - Pf Media
Europe - EMA starts review of cancer medicine Rubraca - RIS.WORLD
PARP-Inhibitor in der Drittlininenbehandlung: EMA prüft Rubraca-Studie – vorerst keine neue Therapie beginnen
Assessment report
Tabrecta (capmatinib) Online Satın Alın - Fiyat & Maliyetler | Everyone.org
EMA Restricts Rubraca's Use Due To Concerns Over Benefit & Safety :: Pink Sheet
BRIEF-EMA Recommends Restricting Use Of Cancer Medicine Rubraca | Law-Order
Rubraca EMEA/H/A-20/1518/C/4272/0033
